ACE-031 is a synthetic protein developed to increase muscle mass and strength by inhibiting myostatin, a regulatory protein that limits muscle growth.
ACE-031 is a synthetic protein designed to block myostatin, a natural protein that limits muscle growth. By inhibiting myostatin, ACE-031 aims to increase muscle mass and strength, making it a possible treatment for muscle-wasting conditions like muscular dystrophy.
It is a fusion protein that combines the activin receptor type IIB with a modified immunoglobulin domain to effectively neutralize myostatin. While early trials showed promising results in boosting muscle volume, its development has faced safety and regulatory challenges. More research is needed to better understand its potential uses and long-term effects.
Ace-031 is a recombinant fusion protein that functions by inhibiting myostatin signalling. Myostatin is a regulatory protein that plays a key role in limiting muscle growth. The peptide functions by acting as a decoy receptor, binding to myostatin and other related proteins, preventing them from interacting with their natural receptor, activin receptor type IIB (ActRIIB).
This inhibition allows for an increase in muscle mass and strength by reducing the natural constraints on muscle growth. The mechanism has potential applications in treating muscle-wasting diseases, as it targets the physiological pathways that regulate muscle size and function.
Buy ACE-031 Peptide Vial
Buy ACE-031 Peptide Ireland 1 mg vial for clinical research use from Direct Sarms. It contains a lyophilized powder which must be reconstituted with bacteriostatic water prior to use.
Buy ACE-031 Pre-Mixed Pen
Buy ACE-031 Peptide Ireland 1 mg Pre-Mixed Pen for research use from Direct Sarms. Available as individual pre-filled cartridges or as a kit which includes a cartridge pen, carry case and pen needle tips.
What is Myostatin?
Myostatin is a protein that plays a crucial role in regulating muscle growth. It is part of the transforming growth factor-beta (TGF-β) superfamily and is primarily produced in skeletal muscle cells. Myostatin acts as a limiting factor for muscle development by inhibiting the differentiation and proliferation of muscle cells. High levels of myostatin reduce muscle mass, while its suppression boosts muscle growth. This makes it a key focus in research on muscle-wasting diseases, athletic performance, and livestock breeding.
What are the differences between ACE-031 and Follistatin 344?
ACE-031 and Follistatin 344 are both inhibitors of myostatin, a protein that regulates muscle mass, but they work differently. ACE-031 is a synthetic protein that blocks myostatin by mimicking its receptor, while Follistatin 344 is a natural glycoprotein that inhibits myostatin and other TGF-beta proteins, potentially offering broader effects on muscle growth. Both are being studied for therapeutic uses, with differences in efficacy and safety.
What are the reported side effects of ACE-031?
Some reported adverse events in trials include nosebleeds, headaches, and reactions at injection sites, amongst other potential risks, highlighting the need for further research.
Can you buy ACE-031 legally?
Use of these products is not approved for human consumption or use and is currently only available for research purposes under controlled conditions. It has not yet been approved by regulatory bodies like the United States Food and Drugs Administration (FDA).
For more information, explore our latest blog posts dedicated to ACE-031 peptides.
Buy ACE-031 peptide from Direct Sarms, a trusted supplier for research-grade peptides. Available in multiple forms, including vials of lyophilized powder, 15 ml and 30 ml nasal sprays, and pre-mixed pens. Designed for laboratory use, ACE-031 offers high purity and quality to support consistent and accurate research results.
We ship these peptides with strict quality control to ensure they stay effective and reliable. Choosing Direct Sarms means you get accurate dosing and trustworthy results for your research.
[1] Kenneth M Attie, Niels G Borgstein, Yijun Yang, Carolyn H Condon, et al (2013) A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers – Muscle Nerve, 2013 Mar, Volume 47 (Issue 3), Pages 416-23.
[2] Hiroyasu Muramatsu, Taichi Kuramochi, Hitoshi Katada, Atsunori Ueyama, et al (2021) Novel myostatin-specific antibody enhances muscle strength in muscle disease models – Scientific Reports , 25 January 2021, Volume 11, Article number: 2160.
[3] Jong Hyeon Yoon and Ki-Sun Kwon (2021) Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics – Endocrinology and Metabolism, 2021, Volume 36 (Issue 3), Pages 478-490.
[4] Samuel M Cadena, Kathleen N Tomkinson, Travis E Monnell, Matthew S Spaits, et al (2010) Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type – Journal of Applied Physiology (1985), 2010 May 13, Volume 109 (Issue 3), Pages 635–642.
[5] Craig Campbell, Hugh J McMillan, Jean K Mah, Mark Tarnopolsky, Kathryn Selby, Ty McClure, et al (2016) Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve, 2017 Apr, Volume 55 (Issue 4), Pages 458-464.
[6] Tero Puolakkainen, Hongqian Ma, Heikki Kainulainen, Arja Pasternack, et al (2017) Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy – BMC Musculoskeletal Disorders, 2017 Jan 19, Volume 18, Page 20.
[7] P Bialek, J Parkington, X Li, D Gavin, et al (2014) A myostatin and activin decoy receptor enhances bone formation in mice – Bone, 2014 Mar, Volume 60, Pages 162-71.
[8] Nelly Béchir, Emilie Pecchi, Christophe Vilmen, Yann Le Fur, et al (2016) ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo – FASEB Journal, 2016 Oct, Volume 30 (Issue 10), Pages 3551-3562.
[9] H Q Han, Xiaolan Zhou, William E Mitch, and Alfred L Goldberg (2013) Myostatin/activin pathway antagonism: molecular basis and therapeutic potential – International Journal of Biochemistry & Cell Biology, 2013 Oct, Volume 45 (Issue 10), Pages 2333-47.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
Worldwide shipping
Visa/Mastercard/Zelle
Cryptocurrency /Transfers
Safe and Secure Shopping
We Distribute From
YOU MUST BE OVER 21 YEARS IN ORDER TO USE THIS WEBSITE. All of the products are to be handled only by properly trained and qualified LABORATORY or RESEARCH professionals.